Initial Problem-Solving Stage Sample Clauses

Initial Problem-Solving Stage. (a) Employees and managers, with or without representation, shall first attempt to resolve any dispute through discussion with the person(s) with whom there is a dispute.
Sample 1Sample 2Sample 3See All (25)
AutoNDA by SimpleDocs
Initial Problem-Solving Stage. The Parties encourage an Employee and their supervisor or manager to discuss a difference where such discussion could lead to the resolution of the difference without the need for a grievance. Every effort should be made to resolve problems at the worksite level prior to going to written grievance. The Parties agree to ensure full explanation of issues during the initial discussion at the worksite level. Failing resolution between the Manager and Employee, the Employee and Manager, along with union representation and Director level management representation, will meet to share relevant information with one another on a without prejudice basis, for the purposes of resolving the dispute before filing a formal grievance. The Director involved at this initial problem solving stage will not be the same Director who hears the grievance. If the difference between the Employer and Individual or Group cannot be resolved at the Initial problem solving stage, the following sequence of steps shall be followed:
Sample 1Sample 2Sample 3
Initial Problem-Solving Stage. If a dispute arises between the Employer and the Employee regarding the interpretation, application or alleged violation of this Collective Agreement, the Employee shall discuss the matter with their immediate Supervisor or designate, who is not within the scope of this Collective Agreement, with a view to resolving it within ten (10) days of the occurrence causing the grievance or within ten (10) days of the time when the Employee first became aware of, or reasonably should have become aware, that a grievance had allegedly occurred. If the dispute is not resolved satisfactorily, it may then be advanced to formal dispute resolution at Step 1.
Sample 1
Initial Problem-Solving Stage. The Parties agree that differences shall be resolved as quickly as possible. It is understood that an Employee has no grievance until they have addressed their concern with their Wellness Manager. Such concern shall be discussed within ten
Sample 1
Initial Problem-Solving Stage. The Parties encourage an Employee and his supervisor or manager to discuss a difference where such discussion could lead to the resolution of the difference without the need for a grievance. Failing resolution between the Manager and Employee, the Employee and Manager, along with union representation and Director level management representation, will meet to share relevant information with one another on a without prejudice basis, for the purposes of resolving the dispute before filing a formal grievance. The Director involved at this initial problem solving stage will not be the same Director who hears the grievance. If the difference between the Employer and Individual or Group cannot be 35 resolved at the Initial problem solving stage, the following sequence of steps shall be followed:
Sample 1

Related to Initial Problem-Solving Stage

  • Problem/ Solution Statement Problem California’s forest health crisis is an emergency of unprecedented scope and scale, with disastrous implications for the state’s environment, economy, energy systems, and human life. Unlike essentially all other technologies and solutions proposed to respond to the crisis, gasification has the potential to process forest waste in a way that extracts value and sequesters a large portion of its carbon. Before the recipient’s development of the pre- commercial Powertainer technology, no one had developed gasification technology that could economically respond to the problem. As a result, there have not yet been any large-scale deployments of distributed, commercial-scale gasification technology. The acceleration of tree mortality and persistent drought conditions make finding solutions to this problem more critical with each passing day.

  • Development or Offering of Renewable Energy Sources Competitive Supplier agrees that it will comply with the applicable provisions of X.X.X. x. 00X, § 00X, § 00 F1/2, and any regulations, orders or policies adopted pursuant thereto.

  • Required Procurement Procedures for Obtaining Goods and Services The Grantee shall provide maximum open competition when procuring goods and services related to the grant-assisted project in accordance with Section 287.057, Florida Statutes.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!